Note: Descriptions are shown in the official language in which they were submitted.
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-1-
Dosage form containing pantoprazole as active ingredient
Technical field
The present invention relates to the field of pharmaceutical technology and
describes a dosage form for
oral administration of the magnesium salt of pantoprazole. The invention
additionally relates to proces-ses
for producing the dosage form.
Prior art
It is generally known to coat peroral administration forms, e.g. tablets or
pellets which contain an acid-
labile active compound, with an enteric coating which, after passage through
the stomach, rapidly
dissolves in the alkaline medium of the intestine. Examples of such acid-
labile active compounds are
acid-labile proton pump inhibitors (H+/K+ ATPase inhibitors), in particular
pyridin-2-ylmethylsulfinyl-
1 H-benzimidazoles, such as are disclosed, for example, in EP-A-0 005 129, EP-
A-0 166 287,
EP-A-0 174 726 and EP-A-0 268 956. On account of their H}/K+ATPase-inhibiting
action, these are of
importance in the therapy of diseases, which are due to increased gastric acid
secretion. Examples of
active compounds from this group which are commercially available are 5-
methoxy-2-[(4-methoxy-3,5-
dimethyl 2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: omeprazole), 5-
difluoromethoxy-2-[(3,4-di-
methoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: pantoprazole), 2[3-
methyl-4-(2,2,2trifluoro-
ethoxy)-2-py(dinyl)methylsulfinyl]-1 H-benzimidazole (INN: lansoprazole) and 2-
{[4-(3-methoxypropoxy)-3-
methylpyridin-2-yl]-methylsulfinyl}-1H-benzimidazole (INN: rabeprazole).
Because of their strong tendency to decompose in a neutral and, in particular,
in an acidic environment,
where strongly colored decomposition products are also formed, for oral
preparations it is also necessary
in this case to protect the active compounds from the action of acids. In the
case of the strongly acid-
labile pyridin-2-ylmethylsulfinyl-1 H-benzimidazoles, it is moreover necessary
to process these in the
tablet core or in pellets in the form of their alkaline salts, for example as
sodium salts, or together with
alkaline substances. Since the substances suitable for enteric coatings are
those having free carboxyl
groups, the problem results that the enteric coating is partly dissolved or
even dissolved from inside
because of the alkaline medium in the interior and the free carboxyl groups
promote the decomposition of
the active compounds. It may therefore be necessary to provide an isolating
intermediate layer
(subcoating) between the enteric coating and the alkaline tablet core or
pellet. It is proposed in
EP-A-0 244 380 to coat cores which contain the active compound together with
alkaline compounds or as
an alkaline salt with at least one layer of nonacidic, inert pharmaceutically
acceptable substances, which
are soluble in water or rapidly decompose in water, before the enteric layer
is applied. The intermediate
layer or intermediate layers act as pH-buffering zones in which the hydrogen
ions diffusing in from outside
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-2-
can react with the hydroxyl ions diffusing from the alkaline core. In order to
increase the buffer capacity of
the intermediate layer, it is proposed to incorporate buffer substances into
the intermediate layer(s). In
practice, it is possible by this process to obtain somewhat stable
preparations. However, relatively thick
intermediate layers are needed in order to avoid the unsightly discolorations
occurring even in the case of
only slight decomposition. Moreover, a considerable effort is to be made in
the preparation to avoid traces
of moisture.
In EP-A-O 519 365, a formulation on the principle of the alkaline core coated
with a water-soluble
intermediate layer and an enteric coating is proposed for the active compound
pantoprazole, in which
improved stability is achieved by use of polyvinylpyrrolidone and/or
hydroxypropylmethylcellulose as
binders for the alkaline core. It is disclosed that as binder a
polyvinylpyrolindone of higher molecular
weight is used.
EP-A-0 342 522 discloses a formulation for acid-sensitive benzimidazoles in
which, between the alkaline
core and the enteric coating, an intermediate layer is located which is
composed of only slightly water-
soluble film-forming material, such as ethylcellulose and polyvinyl acetate,
and a slightly water-soluble
finely granular inorganic or organic material suspended therein, such as, for
example, magnesium oxide,
silicon oxide or sucrose fatty acid esters.
EP-A-0 277 741 describes spherical granules having a core which is coated with
spray powder, which
contains low substituted hydroxypropylcellulose and a benzimidazole compound
having arrti-ulcer activity.
These granules can be coated with an enteric coating agent.
EP-A-1 213 015 discloses an oral pharmaceutical composition with delayed
release of proton pump
inhibitors.
As the abovementioned prior art shows, the production of peroral
administration forms for acid-labile active
compounds requires technically complicated processes.
The International Patent Application W097/41114 describes a specific process
for the preparation of mag-
nesium salts of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. Inter alia, the
preparation of the magnesium
salt of pantoprazole is also described by way of example. According to the
analysis data indicated, the
salt prepared is pantoprazole magnesium in anhydrous form.
International Patent Application W000/10995 describes the dihydrate of the
magnesium salt of panto-
prazole. It is disclosed that the dihydrate of the magnesium salt of
pantoprazole has Inter alia improved
stability properties as in comparison to pantoprazole itself or to
pantoprazole sodium sesquihydrate.
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-3-
Description of the invention
It is an object of the present invention to provide a dosage form for oral
administration of pantoprazole
magnesium salt, which dosage form can be produced without great technical
complexity, which takes
account of the acid lability of pantoprazole and which makes available the
pantoprazole magnesium salt
effectively for the body in such a way that an optimal active ingredient
profile and thus action profile is
achieved.
Pantoprazole magnesium oral pharmaceutical dosage forms, available as delayed
release forms are found
in-vitro to have prolonged dissolution times as compared to corresponding
dosage forms containing
pantoprazole sodium. From a pharmakokinetic point of view it may thus be
expected that pantoprazole
magnesium oral dosage forms may have clinical disadvantages, e.g. delayed
onset of action as
compared to pantoprazole sodium oral dosage forms. Surprisingly, it has been
found now that
pantoprazole magnesium oral dosage forms have unexpected release profiles of
active ingredient and
clinical advantages.
In one aspect the invention therefore relates to an oral pharmaceutical dosage
form comprising
pantoprazole magnesium together with pharmaceutically acceptable excipients.
Surprisingly it has also been found now that oral dosage forms for
pantoprazole magnesium salt
comprising low molecular weight polyvinylpyrrolidone as excipient show
stability and a distinctly improved
release profile for the active ingredient as compared to oral dosage forms for
pantoprazole magnesium
salt known from the art.
The invention therefore also relates to a dosage form for oral administration
of pantoprazole magnesium
salt comprising a therapeutically effective amount of the pantoprazole
magnesium salt together with low
molecular weight polyvinylpyrrolidone and one or more other suitable
pharmaceutical excipients.
A dosage form means, in particular, a medicinal dosage form such as a tablet,
a coated tablet, a multi-
particulate form such as pellets or pellets and microtablets in a capsule or a
multiple unit tableted dosage
form (such as disclosed in WO 96/01623), with the dosage form advantageously
being designed so that
the pantoprazole magnesium salt is released, or made available effectively for
the body, in such a way
that an optimal active ingredient profile, and thus action profile, is
achieved. Unit in connection with the
multiple unit tableted dosage form refers to an individual unit containing the
pantoprazole magnesium salt,
which individual unit can be a small bead, particle, granule or pellet, in
connection with the invention also
referred to as pellet. Suitable dosage forms are for example disclosed in EP-A-
0 519 365, EPA-0 244
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-4-
380, EP-A-1 213 015, EP-A-1 105 105, EP-A-1 037 634, EP-A-1 187 601 and EP-A-1
341 528.
The oral dosage form of the invention is preferably a dosage form with
modified release of the active
ingredient, in particular with delayed release of active ingredient.
Particularly preferred is an enteric coated
dosage form, comprising at least one enteric coating layer which is stable and
does not release the active
ingredient under acidic conditions but rapidly dissolves in neutral conditions
and in particular in the
alkaline medium of the intestine. In a further preferred embodiment the dosage
form according to the
invention in addition to the enteric coating layer contains one or more
intermediate layers (subcoating
layers). In another embodiment the dosage form according to the invention
comprises at least one enteric
coating layer but does not contain an intermediate layer.
Pantoprazole is the INN (International Nonproprietary Name) for the compound 5-
difluoromethoxy-
2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole. The magnesium
salt of pantoprazole is
the chemical compound magnesium bis[5-[difluoromethoxy]-2-[[3,4-dimethoxy-2-
pyridinyl]methyl]sulfinyl]-
1 H-benzimidazolide]. In connection with the invention the pantoprazole
magnesium salt can also be
present in hydrate form (e.g. monohydrate, sesquihadrate or dihydrate). A
particular preferred hydrate in
connection with the invention is the dihydrate of the magnesium salt of
pantoprazole with the chemical
name magnesium bis[5-[difluoromethoxy]-2-[[3,4-dimethoxy-2-
pyridinyl]methyl]sulfinyl]-1Hbenzimi-
dazolide] dihydrate. The synthesis of the magnesium salt of pantoprazole is
described for example in
International Patent Application W097/41114 and the synthesis of the dihydrate
of the magnesium salt of
pantoprazole is disclosed in International Patent Application WO00/10995.
Because of a great tendency to decompose in a neutral and, in particular,
acidic environment, which also
results in highly colored decomposition products, for oral compositions, it is
preferred on the one hand to
keep the magnesium salt of pantoprazole in an alkaline environment and, on the
other hand, to protect it
from exposure to acids. It is generally known to coat tablets or pellets,
which contain an acid-labile active
ingredient with an enteric coating which, after passage through the stomach,
rapidly dissolves in the
alkaline medium in the intestine. In the case of pantoprazole, which is very
acid-labile, it is preferred to
process it in the tablet core or in pellets in the form of its alkaline salts,
and preferably together with
alkaline substances. Since the substances suitable for enteric coatings
contain free carboxyl groups, a
problem arises when the enteric coating is partly or even completely dissolved
from the inside because of
the alkaline medium in the interior, and the free carboxyl groups promote
decomposition of the active
ingredients. It is therefore preferred to provide a sealing intermediate layer
(subcoating) between the
enteric coating and an alkaline tablet or pellet core. EPA 0244380 proposes to
coat cores, which contain
the active ingredient together with alkaline compounds or as alkaline salt
with at least one layer, which is
soluble in water or rapidly disintegrates in water, of nonacidic, inert
pharmaceutically-acceptable
substance before the enteric layer is applied.
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-5-
The intermediate layer or intermediate layers act as pH-buffering zones in
which hydrogen ions, which
diffuse in from the outside, are able to react with the hydroxyl ions which
diffuse out of the alkaline core.
In order to increase the buffer capacity of the intermediate layer, it is
proposed to incorporate buffer
substance into the intermediate layer(s). It is possible in practice by this
method to obtain rather stable
compositions.
The invention therefore also relates to an oral dosage form in pellet or
tablet form for magnesium salt of
pantoprazole comprising a therapeutically effective amount of the magnesium
salt of pantoprazole to-
gether with one or more other pharmaceutical excipients in a pellet or tablet
core, at least one subcoating
(intermediate layer) and an outer enteric layer which is soluble in the small
intestine.
The invention further relates to an oral dosage form in pellet or tablet form
for magnesium salt of panto-
prazole comprising a therapeutically effective amount of the magnesium salt of
pantoprazole together with
one or more other pharmaceutical excipients in an alkaline pellet or tablet
core, at least one subcoating
(intermediate layer) and an outer enteric layer wf'ich is soluble in the small
intestine.
In another embodiment the invention also relates to an oral dosage form in
pellet or tablet form for
magnesium salt of pantoprazole comprising a therapeutically effective amount
of the magnesium salt of
pantoprazole together with polyvinypyrrolidon and optionally one or more other
pharmaceutical excipients
in an alkaline pellet or tablet core, at least one subcoating (intermediate
layer) and an outer enteric layer
which is soluble in the small intestine.
In another embodiment the invention also relates to an oral dosage form in
pellet or tablet form for
magnesium salt of pantoprazole comprising a therapeutically effective amount
of the magnesium salt of
pantoprazole together with PVP90 and optionally one or more other
pharmaceutical excipients in an
alkaline pellet or tablet core, at least one subcoating (intermediate layer)
and an outer enteric layer which
is soluble in the small intestine.
In another embodiment the invention also relates to an oral dosage form in
pellet or tablet form for
magnesium salt of pantoprazole comprising a therapeutically effective amount
of the magnesium salt of
pantoprazole together with low molecular weight polyvinypyrrolidon and
optionally one or more other
pharmaceutical excipients in an alkaline pellet or tablet core, at least one
subcoating (intermediate layer)
and an outer enteric layer which is soluble in the small intestine.
In one embodiment of the invention the oral dosage form is a multiple unit
tableted dosage form, with
individual enteric coating layered units containing pantoprazole magnesium
salt and optionally other
CA 02563162 2010-06-21
r4 I/L'r2UU4Iu UI29
-6-
excipients.
Further suitable pharmaceutical excipients, which may be used in the dosage
form according to the
invention are pharmaceutical excipients such as fillers, (additional) binders,
disintegrants or else, lubri-
cants and release agents. Other suitable excipients, which may be present In
the dosage form of the
Invention are, for example, flavoring substances (such as flavors and
sweeteners), buffer substances, pre-
servatives, coloring substances (such as iron oxid yellow or red), wetting
agents, surfactants (such as
sodium laurylsulfate) or else emulsifiers. Flavors are usually added in a
proportion of from 0.05 to 1% by
weight. Other flavoring substances by way of example are acids such as citric
acid, sweeteners such as
saccharin, aspartame, cyclamate sodium or maltol, which are added according to
the desired result
Suitable binders which can be used for preparing the tablet or pellet core are
polyvinylpyrrolidone (PVP),
hydroxypropymethylcellulose, hydroxypropylcellulose, sodium
carboxymethyloellulose, gelatine, whereby
PVP is preferred.
In a preferred embodiment the Invention also relates to a dosage form for oral
administration of panto-
prazole magnesium salt comprising a therapeutically effective amount of the
pantoprazole magnesium
salt together with polyvinylpyrrolidone (PVP) as a binder and one or more
other suitable pharmaceutical
exciplents.
The polyvinylpynolidone (PVP) employed as binder according to the Invention
can be of molecular weight
In the range of 2.000 -1.500.000. In one embodiment according to the Invention
PVP 90 (average
molecular weight about 1.000.000 -1.500.000) or PVP in the range of from 600
000 to 700 000 can be
mentioned as preferred, In another embodiment of the Invention the PVP is a
water-soluble PVP with a
low average molecular weight and is preferably used as binder In the dosage
form. Low average molecular
weight in connection with the invention refers to PVP with an average
molecular weight below 300 000,
preferably below 100 000, particularly preferably below 70 000, more
particularly preferably below 60 000,
most particularly preferred below 40 000. Examples, which may be mentioned,
are Kolildon 12 PF
(molecular weight 2 000-3 000), Kollidon 17 PF (molecular weight 7 000-11000),
Kollidon 25 (molecular
weight 28 000.34 000) and Kollidon 30 (molecular weight 44 00034 000), whereby
KdUdon 25 Is
preferred.
The proportion on percent by weight based on the finished dosage form) of PVP
as a binder (and, where
appropriate, additional other binders) may preferably be according to the
invention from 0.5 to 15 % by
weight The proportion of PVP Is preferably from f to 5 % by weight,
particularly preferably from 1.5 to 3.5
by weight.
CA 02563162 2010-06-21
r', UP. X &Uvwv~v I
.7.
Suitable fillers in connection with the Invention are mannitol, lactose,
starch, cellulose and calcium phos-
phate, whereby mannitol Is preferred. In one embodiment of the Invention
manntol is the sole filter used
for the oral dosage forms according to the invention.
For a basic reaction of the pellet or tablet core (= alkaline tablet or pellet
core) it is minced (where required
increase in pH is not achieved simply by using an active-Ingredient so with an
Inorganic base. Mention
may be made in this connection of, for example, the pharmacologically-suitable
(tolerable) alkali-metal,
alkaline-earth-metal or earthrmetal salts of weak acids and the
pharmacologically-suitable hydroxides and
oxides of alkaline-earth and earth metals. Sodium carbonate may be mentioned
as a base to be
emphasized by way of example.
Besides filler and binder, other ancillary substances, in particular
lubricants and nonstick agents, and
tablet disintegrants, are used in the manufacture of tablet cores. Examples of
lubricants and nonstick
agents, which may be mentioned, are higher fatty acids and their alkali-metal
and alkaline-earth-metal
salts, such as calcium stearate. Suitable disintegrants are, In particular,
chemically Inert agents. Tablet
disintegrents, which may be mentioned as preferred, are crossliunked
polyvinylpyrrolidone, crosslinked
sodium carboxymethyicelluloses, sodium starch glycolate and pregelatinized
starch.
In one embodiment of the invention the oral dosage form according to the
invention is a tablet and
comprises as exoipients for the tablet core sodium carbonate, mannitol, c
rospovidone,
polyvinylpyrrolidone and calcium stearate.
In another embodiment of the invention the oral dosage form according to the
invention is in pellet form on
the basis of nonpareiiles/seeds and the pellet core comprises starch as
exclpient. It has been found
surprisingly that by using starch as exciplent in the pellet core (based on
nonparetiles/seeds) the release
of the pantoprazole magnesium from the pellet core is faster and Increased as
compared to pellets
without starch in the pellet core. Suitable types of starch, which can be used
in this connection are
different types of starch such as corn starch, potatoe starch, rice starch,
wheat starch, preferably
pregelatinized starch and in particular pregelatinized corn starch (Starch
1500). in a preferred embodiment
according to the invention the amount of pregelatinized starch present in the
pellet core Is In the range of
0.5 - 4% per weight (based on the total weight of the pellet core),
particularly preferably in the range of 1
3% per weight.
The pellet core may contain additional excipients such as those mentioned
above and those mentioned in
connection with tablet cores (e.g. binders, stabilizers, disintegrants,
surfactants and wetting agents).
Wetting agents in this connection preferably refers to s
ynthetic tensides (such as polysorbate, spans,
brij), sulfate- and sulfonate salts of fatty acids (such as sodium
dodecylsuifate), non-ionic tensides (such
Trademark
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-8-
as poloxamer) and glycerol esters of fatty acids. In a preferred embodiment
SIDS (sodium dodecylsulfate)
is present. Binders, which may be present are for example PVP, HPMC,
hydroxypropylcellulose (HPC)
and gelatine. Disintegrants, which may be present are crosslinked
polyvinylpyrrolidone, crosslinked
sodium carboxymethylcelluloses and sodium starch glycolate.
In another embodiment of the invention the oral dosage form according to the
invention comprises as
excipients sodium carbonate, sodium laurylsulfate, pregelatinized starch,
polyvinylpyrrolidone and
sucrose [Pellets]. The oral dosage form is preferably a pellet on the basis of
nonpareilles.
In respect of the intermediate layer(s) to be applied to a pellet core or
tablet core, reference may be made
in particular to those water-soluble layers such as are usually used before
application of layers which are
resistant to gastric juice, or such as are described e.g. in DE-OS 39 01 151.
Examples, which may be
mentioned of film polymers, which can be used for the intermediate layer are
hydroxypropylmethyl-
cellulose and/or polyvinylpyrrolidone, to which plasticizers (such as, for
example, propylene glycol) and/or
other additives (e.g. talc as an anti-sticking agent) and auxiliaries (e.g.
buffers, bases or pigments) can
also be added if desired.
In one embodiment of the invention the oral dosage form according to the
invention comprises
intermediate layer(s) based on hydroxypropylmethylcellulose as film polymer.
The expert knows, on the basis of his technical knowledge, what outer layers,
which are resistant to
gastric juice can be used. Examples of suitable polymers for the enteric
coating are methacrylic
acid/methyl methacrylate copolymer or methacrylic acid/ethyl -acrylate
copolymer (Eudragit L, S, or
Eudragit L30D) or cellulose derivatives, such as carboxymethylethylcellulose
(CMEC, Duodcel ),
cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT),
hydroxypropylmethylcellulose
phthalate (HP50, HPSS), hydroxypropylmethylcellulose acetate succinate
(HPMCAS) or polyvinyl
acetate phthalate, to which it is also possible to add, if desired,
plasticizer (such as propylene glycol or
triethyl citrate) and/or other additives and ancillary substances (e.g.
buffers, bases, such as, preferably,
aluminum hydroxide, or pigments).
In one embodiment of the invention the oral dosage form according to the
invention comprises an enteric
coating based on methacrylic acid/methyl methacrylate copolymer or methacrylic
acid/ethyl -acrylate
copolymer. Eudragit L30D is particularly preferred (Eudragit L30D is
composed of methacrylic acid
copolymer (type C) with molecular weight 250.000, sodium dodecylsulfate and
polysorbate 80).
The layers are applied in conventional ways using equipment customary for
these purposes.
CA 02563162 2010-06-21
..v rvvi,vivvi~ rl.ilL'rLuUglVJV/LY
_9-
The oral dosage form of the invention can be manufactured for example by
processes known to the skilled
worker for producing tablets and pellets (for example as disclosed in the
various patent documents
relating to oral dosage forms for proton pump inhibitors; the process
mentioned in EP-A-0 519 365 or
EP-A-0 244 380 may be mentioned by way of example).
Pellets can be obtained as the can may be by application of a preliminary
Isolation to sucrose starter
pellets and subsequent application of a 10-20% suspension of the active
compound in water with
potyvinylpyrrolidone (PVP) as the binder.
The isolation layer can also be applied, analogously to tablets, using
corresponding ready-made dis-
persions (e.g. opadry) in a fluidized bed coater. The coating with a layer,
which is resistant to gastric
juice, is carried out by a procedure analogous to that for tablets, using
fluidized bed technology.
In one embodiment of the invention, the pharmaceutical dosage form according
to the invention is manu-
factured by producing a suspension of the magnesium salt of pantoprazole in an
aqueous solution of PVP
and spraying the suspension on a mixture of pharmaceutical exciplents to form
granules. In a preferred
embodiment the FVP is low molecular weight PVP.
In the event of further processing the granules to enteric coated tablets the
granules may be processed
together with disintegrant and lubricant components by production processes
familiar to the skilled worker
to tablets and together with film former, plasticizer and coloring agent
components obtaining the enteric
coated tablets according to the invention.
Further subject of the invention is therefore a process for production of an
oral dosage form in form of
tablets or pellets containing the magnesium salt of pantoprazole comprising
the following steps:
(a) production of a suspension of the magnesium salt of pantoprazole
optionally together with further
pharmaceutical exciplents In an aqueous solution of PVP;
(b) providing a mixture of pharmaceutical excipients and
(c) granulation of the mixture obtained from (b) with the suspension obtained
from (a).
In a preferred embodiment the PVP is low molecular weight PVP.
In case of dosage forms of the invention in form of tablets the granules
obtained from (c) may be pressed
after drying and mixing with lubricants and where applicable with further
pharmaceutical exoipients to
tablets on a tableting machine and layered to form enterlo coated tablets.
* Trademark
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-10-
In case of dosage forms of the invention in form of multiparticulates the
granules may be processed into
pellets by extrusion and spheronization. Thereby the magnesium salt of
pantoprazole can be suspended
in the solution of PVP (a) and then mixed with other excipients (c). The
mixture can be processed by
extrusion/spheronization using suitable process equipments. The size of the
obtained core pellets is
approximately between 0.2 and 3 mm and preferably between 0.25 and 2 mm. In a
preferred embodiment
the PVP is low molecular weight PVP.
The manufactured extrusion pellets can further be layered with ingredients
familiar to the skilled worker.
The enteric coated pellets may be processed after drying by production
processes familiar to the skilled
worker to give enteric coated pellets which may be filled in capsules after
mixing with glidants or pressed
to tablets after mixing with further pharmaceutical excipients.
Alternatively, the suspension obtained from (a) may be sprayed on seeds (e.g.
nonparellies comprising
sugar, cellulose or HPMC). The pellets obtained may be processed after drying
by production processses
familiar to the skilled worker to give enteric coated pellets which may be
filled In capsules after mixing
with glidants or pressed into tablets after mixing with further pharmaceutical
excipients.
Particularly preferred the dosage forms of the invention in form of tablets
are produced by granulating a
mixture of mannitol and insoluble PVP with a suspension of the magnesium salt
of pantoprazole, sodium
carbonate and sodium dodecylsulfate in an aqueous solution of PVP, drying the
granules, mixing with
lubricant and pressing into tablets on a tableting machine, followed by'the
coating processes. In one
embodiment the PVP is of low molecular weight.
Particularly preferred the dosage forms of the invention in form of
multiparticulates based on nonpareilles-
technology are produced by spraying a suspension of the magnesium salt of
pantoprazole, sodium
carbonate and sodium dodecylsulfate in an aqueous solution of PVP on starter
pellets, drying the pellets,
layering them with subcoating and enteric coating, mixing with glidants where
applicable and filling into
capsules. In a preferred embodiment the PVP is low molecular weight PVP.
In another embodiment which is also a particularly preferred dosage forms of
the Invention based on
nonpareilles-technology the dosage form is produced by spraying a suspension
of the magnesium salt of
pantoprazole, sodium carbonate, pregelatinized starch and sodium
dodecylsulfate in an aqueous solution
of PVP on starter pellets, drying the pellets, layering them with subcoating
and enteric coating, mixing
with glidants where applicable and filling into capsules. In a preferred
embodiment the PVP is low
molecular weight PVP.
Particularly preferred the dosage forms of the invention in form of extrusion
pellets are produced by granu-
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-11-
lating a mixture of microcrystalline cellulose, sodium carbonate, sodium
starch glycolate, sodium
carboxymethylcellulose with a suspension of the magnesium salt of pantoprazole
in an aqueous solution
of PVP, extruding the wet mass and rounding it using a spheronizer or
marumerizer. The obtained pellet
cores are dryed using a fluid bed dryer or other suitable drying techniques.
Afterwards the pellets are
layered with subcoating and gastric resistant coating, mixed with glidarits
where applicable and filled into
capsules. In a preferred embodiment the PVP is low molecular weight PVP.
In an other embodiment of the invention the pharmaceutical form of the
invention in form of tablets is
produced by granulating a dry mixture of the magnesium salt of pantoprazole
and pharmaceutical ex-
cipients with an aqueous solution of PVP, drying the granules and mixing them
with further pharma-
ceutical excipients where applicable. The granules may be compressed into
tablets on a tableting
machine after mixing with further pharmaceutical excipients. Preferably the
granulation is proceeded
using a fluid bed granulator under convenient conditions. In a preferred
embodiment the PVP is low
molecular weight PVP.
Subject of the invention is therefore also a process to produce an oral dosage
form in form of tablets or
multiparticulates containing the magnesium salt of pantoprazole comprising the
following steps:
(a) production of a dry mixture of the magnesium salt of pantoprazole and
pharmaceutical excipients and
(b) granulating the mixture obtained from (a) with an aqueous solution of PVP.
In a preferred embodiment the PVP is low molecular weight PVP.
In case of dosage forms of the invention in form of extrusion pellets the
aforementioned mixture may be
processed into pellets by extrusion and spheronization. Thereby the magnesium
salt of pantoprazole can
be mixed with other excipients (a) and granulated with an aqueous solution of
PVP (b). In a preferred
embodiment the PVP is low molecular weight PVP. The mixture can be processed
by extrus-
ion/spheronization using suitable process equipments. The size of the obtained
core pellets is approx-
imately between 0.2 and 3 mm and preferably between 0.25 and 2 mm.
Particularly preferred the dosage forms of the invention in form of tablets
are produced by granulating a
mixture of the magnesium salt of pantoprazole, mannit and sodium carbonate and
insoluble PVP using
an aqueous solution of PVP, drying the granules, mixing with lubricants and
pressing Into tablets on a
tableting machine, followed by the coating processes. In a preferred
embodiment the PVP is low
molecular weight PVP.
Particularly preferred the dosage forms of the invention in form of extrusion
pellets are produced by
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-12-
granulating a dry mixture of microcrystalline cellulose, sodium carbonate,
sodium starch glycolate,
sodium carboxymethylcellulose and the magnesium salt of pantoprazole with an
aqueous solution of
PVP, extruding the wet mass and rounding it using a spheronizer or
marumerizer. The obtained pellet
cores are dryed using a fluid bed dryer or other suitable drying techniques,
followed by the above
mentioned coating processes. In a preferred embodiment the PVP is low
molecular weight PVP.
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-13-
Description of the figures
Figure 1
Figure 1 shows the release of the magnesium salt of pantoprazole from tablet
cores containing different
types of PVP with different molecular weights. The granules of example B9 were
produced by granulating
them using a suspension of the magnesium salt of pantoprazole in an aqueous
solution of PVP. The
granules of the examples B8, B10, 1311, B12 and the reference example C1 were
produced by granulating
a dry mixture of the magnesium salt of pantoprazole and pharmaceutical
excipients using an aqueous
solution of PVP.
Figure
2
Figure 2 shows the difference in release of the magnesium salt of pantoprazole
from a tablet compared to
the release of the sodium salt of pantoprazol from a tablet with comparable
composition.
The production of dosage forms according to the invention is described by way
of example below. The
following examples explain the invention in more detail without restricting
it.
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-14-
Examples
A. Synthesis of Magnesium bisf5-fdifluoromethoxyl-2-113.4-dimethoxy2-
gyridinyll-
methyllsulfinyl]-1H-benzimidazolidel dehydrate
3.85 kg (8.9 mol) of pantoprazole Na sesquihydrate [sodium [5-
[difluoromethoxy]-2-[[3,4-dimethoxy-
2-pyridinyl]methyl]sulfinyl]-1 H-benzimidazolide]sesquihydrate] are dissolved
at 20-25 C in 38.5 I of purified
water in a stirring vessel. A solution of 1.0 kg (4.90 mol) of magnesium
dichloride hexahydrate in 8 I of
purified water is added with stirring at 20-30 C in the course of 3 to 4 h.
After stirring for a further 18 h, the
precipitated solid is centrifuged, washed with 23 I of purified water, stirred
at 20-30 C for 1 to 2 h in 351 of
purified water, centrifuged again and washed again with 30-50 I of purified
water. The solid product is dried
at 50 C in vacuo (30-50 mbar) until a residual water content of < 4.8% is
achieved. The product is then
ground.
The title compound is obtained as a white to beige powder, which is employed
directly for further
pharmaceutical processing.
Yield: 3.40 kg (90% of theory); water content: 4.5-4.6%; melting point:194-196
C with decomposition.
CHN analysis C H N S
Theory 46.58 3.91 10.19 7.77
Found 46.33 3.89 10.04 7.83
Alternatively the title compound can be produced using mixtures of organic
solvents with water. For this,
pantoprazole Na sesquihydrate is dissolved in an organic solvent at 50-60 C.
0.5 mole equivalents of the
magnesium salt (e. g. magnesium chloride hexahydrate), dissolved in water, are
added drop by drop and
the solution is allowed to cool with stirring. The precipitated solid is
filtered off, washed with the
corresponding organic solvent and is dried in vacuo at 50 C to constant
weight. The title compound is
obtained as a colourless powder. Examples for different solvents are given in
the following table 1.
Table 1:
pantoprazole Na organic water yield of title compound melting point water
content
sesquihydrate solvent C %
50 g isopropanol 300 ml 45,4 g 196 -197 4,4-4,5
1 300 ml
50 g isopropanol 120 ml 45,9 g 196-197 4,3
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-15-
pantoprazole Na organic water yield of title compound melting point water
content
sesquihydrate solvent C %
300 ml
50 g ethanol 300 ml 45,8 g 197-198 4,6
300 ml
50 g aceton 300 ml 45,6 g 195 -196 4,6,-4,7,
300 ml
Alternatively the title compound can be produced by reacting pantoprazole with
a basic magnesium salt,
such as magnesium methylate, for example in the following manner: 90 g of
pantoprazole are dissolved in
700 ml of 2-propanol at 60-70 C. 13.4 g (0.5 moles) of solid magnesium
methylate are added, the solution
is allowed to cool with stirring and filtered. After addition of 36 ml of
water the crystalline solid formed is
filtered off, washed with water and dried in vacuo at 50 C to constant weight.
The title compound of
melting point 194-196 C (water content 4.8 %) is obtained as beige solid.
B. Production of dosage forms according to the invention
Example B.1
Pellets made by Wurster coating (Nonpareilles):
I. Active pellets:
a.) Sucrose starter pellets (0.425-0.5 mm) 500.0 g
b.) Sodium carbonate 30.0 g
c.) Pantoprazole-Mg dihydrate 300.0 g
d.) Polyvinylpyrrolidone K 25 35.0 g
a. is sprayed with an aqueous dispersion of b., c. and d. in a fluidised bed
process (Wurster equipment)
or other suitable equipments (e.g. coating pan).
II. Intermediate layer (subcoating):
e.) Hydroxypropylmethylcellulose 120.0 g
f.) Titanium dioxide 2.0 g
g.) LB Iron oxide yellow 0.2 g
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-16-
h.) Propylene glycol 24.0 g
e. is dissolved in water (A). f. and g. are suspended in water using a high
shear mixer (B). A and B are
combined and after addition of h. the resulting suspension is sieved through a
suitable sieve. The
suspension is sprayed onto 500 g of the active pellets obtained under I using
a fluidised bed process
(Wurster) or other suitable processes (e.g. coating pan).
Ill. Coating with a layer which is resistant to gastric juice (Enteric
coating):
L) Eudragit L 30 D 230.0 g
j.) Triethyl citrate 7.0 g
i. is suspended in water and after addition of j. the resulting dispersion is
sieved through a suitable sieve.
Ill is sprayed onto 500 g of the isolated pellets obtained under II in a
Wurster fluidised bed-apparatus or
other suitable equipments (e.g. coating pan).
The resulting enteric coated pellets could be filled in hard gelatine capsules
of suitable size (e.g. size 2)
or tableted using suitable tableting ingredients (e.g. microcrystalline
cellulose or lactose monohydrate) on
a prevalent tablet press (see examples B6/7).
Example B.2
Pellets made by Wurster coating (Nonpareilles):
1. Active pellets:
a.) Cellulose pellets (0.6-0.7 mm) 1000.0 g
b.) Sodium carbonate 75.0 g
c.) Pantoprazole-Mg dihydrate 650.0 g
d.) Polyvinylpyrrolidone K 25 80.0 g
a. is sprayed with an aqueous dispersion of b., c. and d. in a fluidised bed
process (Wurster equipment)
or other suitable equipments (e.g. coating pan).
II. Intermediate layer (subcoating):
e.) Hydroxypropylmethylcellulose 250.0 g
f.) Titanium dioxide 5.0 g
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-17-
g.) LB Iron oxide yellow 0.45 g
e. is dissolved in water (A). f. and g. are suspended in water using a high
shear mixer (B). A and B are
combined and the resulting suspension is sieved through a suitable sieve. The
suspension is sprayed
onto 1000 g of the active pellets obtained under I using a fluidised bed
process (Wurster) or other suitable
processes (e.g. coating pan).
III. Coating with a layer which is resistant to gastric juice (Enteric
coating):
h.) Eudrag'rt L 30 D 365.0 g
i.) Triethyl citrate 15.0 g
h. is suspended in water and after addition of i. the resulting dispersion is
sieved through a suitable sieve.
III is sprayed onto 1000 g of the isolated pellets obtained under II in a
Wurster fluidised bed-apparatus or
other suitable equipments (e.g. coating pan).
The resulting enteric coated pellets could be filled in hard gelatine capsules
of suitable size (e.g. size 2)
or tableted using suitable tableting ingredients (e.g. microcrystalline
cellulose or lactose monohydrate) on
a prevalent tablet press (see examples B6/7).
Exam Ip a B.3
Pellets made by Wurster coating (Nonpareilles):
1. Active pellets:
a.) Cellulose pellets (0.40.5 mm) 2000.0 g
b.) Sodium carbonate 136.0 g
c.) Pantoprazole-Mg dihydrate 1420.0 g
d.) Polyvinylpyrrolidone K 25 117.0 g
e.) Sodium dodecylsulfate (SDS) 16.4 g
To produce core material, suspension layering is performed in a fluid bed
apparatus or other suitable
equipment as described in example 131.
II. Intermediate layer (subcoating):
f.) Hydroxypropylmethylcellulose 600.0 g
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-18-
g.) Polyvinylpyrrolidone K 25 8.0 g
h.) Titanium dioxide 10.0 g
i.) LB Iron oxide yellow 1.0 g
The pellets covered with intermediate layer are produced as described in
example 131.
III. Coating with a layer which is resistant to gastric juice (Enteric
coating):
j.) Hydroxypropylmethylcellulose acetate succinate 800.0 g
k.) Triethyl citrate 250.0 g
I.) Ethanol 7250.0 g
The enteric coating layer is applied to the isolated pellets using fluidized
bed equipment from a
water/ethanol solution.
The resulting enteric coated pellets could be filled in hard gelatine capsules
of suitable size (e.g. size 2)
or tableted using suitable tableting ingredients (e.g. microcrystalline
cellulose or lactose monohydrate) on
a prevalent tablet press (see examples B6/7).
Example B.4
Pellets made by extrusion/spheronization:
1. Manufacture of pellets using extrusion/spheronization:
a.) Pantoprazole-Mg dihydrate 250.0 g
b.) Microcrystalline cellulose 150.0 g
c.) Sodium starch glycolate 20.0 g
d.) Sodium carbonate 32.5 g
e.) Sodium carboxymethylcellulose 25.0 g
f.) Polyvinylpyrrolidone K 25 35.0 g
a.-c. are mixed using a suitable mixer. d. f. are dissolved in water and the
resulting binder solution is
added to the powder mixture. After addition of the solution and mixing the
mass is extruded using a
screw extruder, Afterwards the granules are rounded using a spheronizer and
dryed in a fluidised bed
apparatus.
II. Intermediate layer (subcoating):
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-19-
The application of the intermediate layer is carried out by a procedure
analogus to that described for the
nonpareilles pellets (example B1 to B3) using fluidised bed or other suitable
equipment.
Ill. Coating with a layer which is resistant to gastric juice:
The application of the gastric resistant layer is carried out by a procedure
analogus to that described for
the nonpareilles pellets (example 131 to B3) using fluidised bed or other
suitable equipment.
The resulting enteric coated pellets could be filled in hard gelatine capsules
of suitable size (e.g. size 2)
or tableted using suitable tableting ingredients (e.g. microcrystalline
cellulose or lactose monohydrate) on
a prevalent tablet press (see examples B617).
Example B.5
Pellets made by extrusion/spheronization:
1. Manufacture of pellets using extrusion/spheronization:
a.) Pantoprazole-Mg dehydrate 1300.0 g
b.) Microcrystalline cellulose 700.0 g
c.) Lactose monohydrate 150.0 g
d.) Hydroxypropylmethylcellulose 110.0 g
e.) Sodium carbonate 180.0 g
f.) Pregelatinized starch 125.0 g
g.) Polyvinylpyrrolidone K 25 200.0 g
The extrusion pellets are produced as described in example B4.
II. Intermediate layer (subcoating):
The application of the intermediate layer is carried out by a procedure
analogus to that described for the
nonpareilles pellets (example BI to B3) using fluidised bed or other suitable
equipment.
Ill. Coating with a layer which is resistant to gastric juice:
The application of the gastric resistant layer is carried out by a procedure
analogus to that described for
the nonpareilles pellets (example 131 to B3) using fluidised bed or other
suitable equipment.
The resulting enteric coated pellets could be filled in hard gelatine capsules
of suitable size (e.g. size 2)
or tableted using suitable tableting ingredients (e.g. microcrystalline
cellulose or lactose monohydrate) on
a prevalent tablet press (see examples B6/7).
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-20-
Example B.6
Multiple unit tableted dosage form made from Nonpareilles -Pellets:
1. Active pellets:
a.) Cellulose pellets (0.6-0.7 mm) 2500.0 g
b.) Sodium carbonate 180.0 g
c.) Pantoprazole-Mg dihydrate 1700.0 g
d.) Polyvinylpyrrolidone K 25 250.0 g
e.) Sodium dodecylsulfate 18.0 g
a. is sprayed with an aqueous dispersion of b., c., d. and e. in a fluidized
bed process (Wurster
equipment) or other suitable equipments (e.g. coating pan).
II. Intermediate layer (subcoating):
f.) Hydroxypropylmethylcellulose 600.0 g
g.) Talcum (micronized) 100.0 g
h.) Magnesium stearate 80.Og
f. is dissolved in water (A). g. and h. are suspended in water using a high
shear mixer (B). A and B are
combined and the resulting suspension is sieved through a suitable sieve. The
suspension is sprayed
onto 2500 g of the active pellets obtained under I using a fluidised bed
process (Wurster) or other suitable
processes (e.g. coating pan).
Ill. Coating with a layer which is resistant to gastric juice (Enteric
coating):
1.) Methacrylic acid copolymer 925.0 g
j.) Polyethylene glycole 400 28.0 g
i. is suspended in water and after addition of j. the resulting dispersion is
sieved through a suitable sieve.
Ill is sprayed onto 2500 g of the isolated pellets obtained under II in a
Wurster fluidised bed-apparatus or
other suitable equipments (e.g. coating pan).
IV. Tablets:
k.) Microcrystalline cellulose 3750.0 g
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-21-
I.) Crosslinked polyvinylpyrrolidone 100.0 g
m.) Magnesium stearate 7.0 g
2500 g of enteric coated pellets are mixed with the tableting excinpients and
compressed into tablets
using a single punch tableting machine equipped with 11 mm round punches. The
amount of pantoprazole
is approx. 20 mg.
Example B.7
Multiple unit tableted dosage form made from Extrusion-Pellets:
1. Manufacture of pellets using extrusion/spheronization:
a.) Pantoprazole-Mg dihydrate 433.0 g
b.) Microcrystalline cellulose 240.0 g
c.) Lactose monohydrate 55.0 g
d.) Hydroxypropylmethylcellulose 35.0 g
e.) Sodium carbonate 60.0 g
f.) Sodium dodecylsulfate 5.5 g
g.) Pregelatinized starch 35.0 g
h.) Polyvinylpyrrolidone K 25 70.0 g
The extrusion pellets are produced as described in example B5.
II. Intermediate layer (subcoating):
i.) Hydroxypropylmethylcellulose 190.0 g
j.) Polyvinylpyrrolidone K 25 8.0 g
j.) Talcum (micronized) 32.0 g
k.) Magnesium stearate 14.Og
The application of the intermediate layer is carried out by a procedure
analogus to that described for the
nonpareilles pellets (example B1 to B3) using fluidised bed or other suitable
equipment.
Ill. Coating with a layer which is resistant to gastric juice (Enteric
coating):
I.) Methacrylic acid copolymer 296.0 g
m.) Glycerol triacetate 28.0 g
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-22-
The application of the gastric resistant layer is carried out by a procedure
analogus to that described for
the nonpareilles pellets (example 131 to B3) using fluidised bed or other
suitable equipment.
IV. Tablets:
n.) Microcrystalline cellulose 1200.0 g
o.) Crosslinked polyvinylpyrrolidone 32.0 g
p.) Polyethyleneglycole 4000 38.0 g
q.) Magnesium stearate 4.5 g
The enteric coated extrusion pellets are tableted with the above tableting
excipients as described in
example B6 of an amount of approximately 40 mg pantoprazole.
Example B.8
Tablets:
1. Tablet Core:
a.) Pantoprazole-Mg dihydrate 43.04 mg
b.) Sodium carbonate 5.55 mg
c.) Mannitol 52.66 mg
d.) Crospovi done 40.00 mg
e.) Polyvinylpyrrolidone K 25 5.00 mg
f.) Purified water 7.42 mg
g.) Calcium stearate 3.00 mg
a. is dry-mixed with a part of b., a part of c. and d. and put in the vessel
of a fluid bed granulator; e. is
dissolved in f. together with the other part of b. and c. to form the
granulation liquid. The solution is
sprayed on the mixture under convenient conditions. After drying and mixing
with g. the mixture is
pressed into tablets using a rotary tableting machine equipped with 7 mm round
punches. Tablet weight
is approx. 156.7 mg, corresponding to 40 mg pantoprazole (i.e. 43.04 mg
pantoprazole-Mg dihydrate).
U. Intermediate layer (subcoating):
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
.23-
h.) Hydroxypropylmethylcellulose 11.87 mg
i.) Polyvinylpyrrolidone K 25 0.24 mg
j.) Titanium dioxide 0.21 mg
k.) LB Iron oxide yellow 0.02 mg
I.) Propylene glycol 2.66 mg
h. is dissolved in water (A). j. and k. are suspended in a solution of i. in
water using a high shear mixer
(B). After sieving of B, A and B are combined I. is added to the suspension.
The suspension is sprayed
onto the tablet cores obtained under I using a coating pan.
III. Coating with a layer which is resistant to gastric juice (Enteric
coating):
m.) Eudragit L 30 D 7.27 mg
n.) Triethyl citrate 0.73 mg
n. is suspended in water and mixed m. III is sprayed onto the isolated tablets
obtained under II using a
coating pan.
Example B.9
Tablets:
1. Tablet Core:
a.) Pantoprazole-Mg dihydrate 43.04 mg
b.) Sodium carbonate 5.55 mg
c.) Mannitol 51.94 mg
d.) Crospovidone 40.00 mg
e.) Polyvinylpyrrolidone K 25 5.00 mg
f.) Sodium dodecylsulfate 0.72 mg
g.) Purified water 7.42 mg
h.) Calcium stearate 3.00 mg
f. and a part of b. are dissolved in water, a part of c. is added and a. is
suspended in the solution. A
solution of e. in water is added to the suspension. The other part of b. and
c. is mixed with d. and the
mixture is put in the vessel of a fluid bed granulator. The suspension is
sprayed on the mixture under
convenient conditions. After drying and mixing with h. the mixture is
compressed into tablets using a
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-24-
rotary tableting machine equipped with 7 mm round punches. Tablet weight is
approx. 156.7 mg.
The tablet cores are isolated and layered with an enteric coating as described
in Example B8.
Example B.10
Tablets:
1. Tablet Core:
a.) Pantoprazole-Mg dihydrate 43.04 mg
b.) Sodium carbonate 5.55 mg
c.) Mannitol 52.66 mg
d.) Crospovidone 40.00 mg
e.) Polyvinylpyrrolidone K 30 5.00 mg
f.) Purified water 7.42 mg
g.) Calcium stearate 3.00 mg
The tablet cores are produced as described in example B8.
The tablet cores are layered with an isolating coating and an enteric coating
as described in example B8.
Example B.11
Tablets:
1. Tablet Core:
a.) Pantoprazole-Mg dihydrate 43.04 mg
b.) Sodium carbonate 5.55 mg
c.) Mannitol 52.66 mg
d.) Crospovidone 40.00 mg
e.) Polyvinylpyrrolidone K 17 5.00 mg
f.) Purified water 7.42 mg
g.) Calcium stearate 3.00 mg
The tablet cores are produced as described in example B8.
The tablet cores are layered with an isolating coating and an enteric coating
as described in example B8.
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
_25.
Example 8.12
Tablets:
1. Tablet Core:
a.) Pantoprazole-Mg dihydrate 43.04 mg
b.) Sodium carbonate 5.55 mg
c.) Mannitol 52.66 mg
d.) Crospovidone 40.00 mg
e.) Polyvinylpyrrolidone K 12 5.00 mg
f.) Purified water 7.42 mg
g.) Calcium stearate 3.00 mg
The tablet cores are produced as described in example B8.
The tablet cores are layered with an isolating coating and an enteric coating
as described in example B8.
Example B.13
Tablets:
1. Tablet Core:
a.) Pantoprazole-Mg dihydrate 43.04 mg
b.) Sodium carbonate 5.55 mg
c.) Lactose 55.00 mg
d.) Crospovidone 35.00 mg
e.) Polyvinylpyrrolidone K 25 5.00 mg
f.) Purified water 7.42 mg
g.) Calcium stearate 3.00 mg
The tablet cores are produced as described in example B8. Tablet weight
approx. 154 mg.
II. Intermediate layer (subcoating):
h.) Hydroxypropylmethylcellulose 12.20 mg
i.) Titanium dioxide 0.21 mg
j.) LB Iron oxide yellow 0.02 mg
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-26-
h. is dissolved in water (A). I. and j. are suspended in water using a high
shear mixer (B). A and B are
combined and the resulting suspension is sieved through a suitable sieve. The
suspension is sprayed
onto the tablet cores obtained under I using a coating pan.
The isolated tablet cores are layered with an enteric coating as described in
example B8.
Example B.1 4
Tablets:
1. Tablet Core:
a.) Pantoprazole-Mg dehydrate 43.04 mg
b.) Trinatriumphosphate 5.55 mg
c.) Mannitol 55.00 mg
d.) Crospovidone 40.00 mg
e.) Polyvinylpyrrolidone K 25 5.00 mg
f.) Purified water 7.42 mg
g.) Magnesium stearate 3.00 mg
The tablet cores are produced as described in example B8. Tablet weight
approx. 159 mg.
II. Intermediate layer (subcoating):
The tablet cores are layered with an isolating coating as described in example
B8.
III. Coating with a layer which is resistant to gastric juice (Enteric
coating):
m.) Methacrylic acid copolymer 6.5 mg
n.) Glycerol triacetate 0.65 mg
The application of the gastric resistant layer is carried out as described in
example B8.
Example B.1 5
1. Tablet core
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-27-
a) Pantoprazole-Mg dihydrate 43,04 mg
b) Sodium carbonate 5,55 mg
c) Mannitol 52,66 mg
d) Crospovidone 40,00 mg
e) PVP 90 (povidone) 5,00 mg
1) Calcium stearate 3,00 mg
a) is mixed with some of b), c) and the complete amount of d). The remainders
of b) and c) are added to a
clear aqueous solution of e). Granules are obtained with this solution in a
fluidized bed. f) is added to the
dry granules and the granules are pressed on a suitable tablet- press.
II. Preliminary isolation (intermediate layer)
g) HPMC 2910,3 cps 11,87 mg
h) PVP 25 0,24 mg
i) Titanium dioxide 0,21 mg
j) Iron oxide yellow 100 E 172 0,02 mg
k) Propylene glycol 2,66 mg
Total weight per preisolated core 172 mg
g) is dissolved in water and h) is added and also dissolved (A). i) and j) are
suspended in water using a
suitable stirrer (B). A and B are combined. After addition of k), the
suspension is sieved immediately
before further processing, during which the tablet cores obtained under I. are
coated to an adequate
thickness of the intermediate layer in a suitable coating apparatus.
III. Coating with a layer which is resistant to gastric juice
I) Eudragit L 30 D 7,27 mg
m) Triethyl citrate 0,73 mg
Total weight per film-coated tablet 180 mg
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-28-
resistant to gastric juice
I) is diluted with water and m) is added. The dispersion is sieved before
processing.
The preisolated tablets are sprayed in suitable coating apparatuses using the
obtained dispersion.
Example B.16
Pellets made by Wurster coating (Nonpareilles):
1. Active pellets:
a.) Sucrose starter pellets (0.71-0.85 mm) 4.0 kg
b.) Sodium carbonate 0.27 kg
c.) Pantoprazole-Mg dihydrate 2.84 kg
d.) Polyvinylpyrrolidone K 25 0.23 kg
e.) Pregelatinized starch 0.22 kg
f.) Sodium dodecylsulfate 0.03 kg
a. is sprayed with an aqueous dispersion of the other ingredients in a
fluidised bed process (Wurster
equipment) or other suitable equipments (e.g. coating pan).
II. Intermediate layer (subcoating):
g.) Hydroxypropylmethylcellulose 1.830 kg
h.) Titanium dioxide 0.028 kg
i.) LB Iron oxide yellow 0.003 kg
j.) Polyvinylpyrrolidone K25 0.021 kg
g. and j. are dissolved in water (A). h. and i. are suspended in water using a
high shear mixer (B). A and
B are combined and the resulting suspension is sieved through a suitable
sieve. The suspension is
sprayed onto the active pellets obtained under I using a fluidised bed process
(Wurster) or other suitable
processes (e.g. coating pan).
III. Coating with a layer which is resistant to gastric juice (Enteric
coating):
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-29-
k.) Eudragit L 30 D 4.40 kg
I.) Triethyl citrate 0.13 kg
m.) Talcum 0.06 kg
k. is suspended in water and after addition of I. the resulting dispersion is
sieved through a suitable sieve.
The dispersion is sprayed on the isolated pellets obtained under II in a
Wurster fluidised bed-apparatus or
other suitable equipments (e.g. coating pan).
The resulting enteric coated pellets are mixed with talcum (m) and could be
filled in hard gelatine
capsules of suitable size (e.g. size 2) or tableted using suitable tableting
ingredients (e.g.
microcrystalline cellulose or lactose monohydrate) on a prevalent tablet
press.
C. Physical investigations and comparative tests with dosage forms in which
high molecular
weight PVP was used as binder
Example C.1
Tablets:
1. Tablet Core:
a.) Pantoprazole-Mg dihydrate 43.04 mg
b.) Sodium carbonate 5.55 mg
c.) Mannitol 52.66 mg
d.) Crospovidone 40.00 mg
e.) Polyvinylpyrrolidone K 90 5.00 mg
f.) Purified water 7.42 mg
g.) Magnesium stearate 3.00 mg
The tablet cores are produced as described in example B8.
The tablet cores are layered with an isolating coating and an enteric coating
as described in example B8.
Example C.2
1. Tablet core
CA 02563162 2010-06-21
TV %-f 4VV`tlV7VJ7Y rt,l,L`rLUu4/uJV,4Y
.=0-
a) Pantoprazole-Na sesquihydrate 45,10 mg
b) Sodium carbonate 10,00 mg
c) Mannitol 42,70 mg
d) Crospovidone 50,00 mg
e) PVP 90 (povidone) 4,00 mg
f) Calcium stearate 3,20 mg
a) is mixed with some of b), c) and d). The remainders of b) and c) are added
to a clear aqueous solution
of e). Granules are obtained with This solution in a fluidized bed. The
remainder of d) and f) am added to
the dry granules and the granules are pressed on a suitable tablet press.
II. Preliminary isolation (intermediate layer)
g) HPMG 2910,3 cps 19,00 mg
h) PVP 25 0,38 mg
I) Titanium dioxide 0,34 mg
j) Iron oxide yellow 100 E 172 0,03 mg
k) Propylene glycol 4,25 mg
Total weight per preisolated core 188 mg
g) is dissolved in water and h) is added and also dissolved (A).1) and ii are
suspended In water using a
suitable stirrer (B). A and B are combined. After addition of k), the
suspension is sieved immediately
before further processing, during which the tablet cores obtained under 1. are
coated to an adequate
thickness of the intermediate layer In a suitable coating apparatus.
Ill. Coating with a layer which is resistant to gastric juice
1) Eudragit L 30 D 14,56 mg
m) Triethyl citrate 1,45 mg
Trademark
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-31 -
Total weight per film-coated tablet 204 mg
resistant to gastric juice
l) is diluted with water and m) is added. The dispersion is sieved before
processing.
The preisolated tablets are sprayed in suitable coating apparatuses using the
obtained dispersion.
The release of the magnesium salt of pantopazole was determined for tablet
cores corresponding to
example B8, B9, B10, 1311 and B12 compared to a tablet core corresponding to
example C1.
Disintegration of tablet cores: the disintegration of tablet cores was
determined as described in the
European Pharmacopoeia.
Release of active ingredient: the release of active ingredient was determined
as described in the US
Pharmacopoeia (USP XXV; apparatus 2; phosphate buffer pH 6.8; 100 rpm).
The release of the formulations according to example B15 and C2 was determined
after 2 hours in 0.1 N
hydrochloric acid and 1 hour in phosphate buffer pH 6.8; 100 rpm). In Figure 2
only the drug release in
phosphate buffer is shown.
Result: The disintegration results are shown in Table 1, the dissolution
profiles are shown in Figure 1.
Table 1
Example PVP used as binder Disintegration [min]
B8 PVP 25 7
B9 PVP 25 6.5
B10 PVP 30 10.5
1311 PVP 17 9
B12 PVP 12 7.5
C1 PVP 90 10.5
Surprisingly, the dissolution of the magnesium salt of pantoprazole from
tablet cores in which low
molecular weight PVP was used as binder is faster than from tablet cores in
which high molecular weight
PVP was used although the disintegration for all tablet cores is below 15
minutes.
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-32-
D. Physical investigations and comparative tests with dosage forms
contaningpantoprazole
sodium sesquihydrate and pantoprazole magnesium dehydrate
Figure 2 shows the difference in release of the magnesium salt of pantoprazole
from a tablet compared to
the release of the sodium salt of pantoprazol from a tablet with comparable
composition. The dosage form
having the sodium salt of pantoprazole as active ingredient (example C.2)
shows after a short lag time an
immediate and complete release of the active ingredient. Surprisingly the
dosage form containing the
magnesium salt of pantoprazole does not have a lag time in release of active
compound and shows a
constant release of active ingredient over whole period.
E. Results of Clinical Study
Healing of patient suffering from GERD (gastro-oesophageal reflux disease) Ito
III (according to
Savary/Miller classification modified by Siewert) after treatment with
pantoprazole magnesium dihydrate
40 mg o.d. (dosage form according to the invention) in comparision with a
corresponding pantoprazole
sodium sesquihydrate 40 mg o.d. dosage form have been studied. Surprisingly it
has been found that
pantoprazole magnesium dihydrate formulation is superior to pantoprazole
sodium sesquihydrate
formulation in the healing of GERD Ito III, whereby safety is comparable for
both dosage forms.
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-33-
Industrial applicability
The dosage forms according to the invention containing the magnesium salt of
pantoprazole can be
employed for the treatment and prevention of all the diseases, which are
regarded as treatable or avoid-
able by the use of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. In
particular, such dosage forms
according to the invention can be employed in the treatment of stomach
disorders. Examples which may
be mentioned in connection with the invention are the treatment or prophylaxis
of benign gastric ulcer,
gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, duodenal ulcer,
duodenal ulcer associated
with Helicobacter pylori, prophylaxis of NSAID-associated gastric or duodenal
ulcer in patients with an
increased risk of gastroduodenal complication who require continued NSAID
treatment or combination
therapy with antibiotics in the eradication of Helicobacter pylori. Such
dosage forms according to the
invention contain between I and 500 mg, preferably between 5 and 100 mg,
particularly preferable
between 5 and 80 mg of the pantoprazole. Examples which may be mentioned are
tablets or capsules
which contains the pantoprazole magnesium salt in an amount corresponding to
10, 20, 40, 50, 80 or 100
mg of pantoprazole (free acid). The administration of the daily dose (e.g. 40
mg of active compound) can
be carried out, for example, in the form of an individual dose or by means of
a number of doses of the
administration forms according to the invention (e.g. 2 times 20 mg of active
compound).
The invention therefore also relates to a method for the prophylaxis or
treatment of a clinical condition in a
mammal, such as a human, for which a proton pump inhibitor is indicated, which
comprises
administration of a therapeutically effective amount pantoprazole magnesium in
a dosage form according
to the invention. In one embodiment the clinical condition is selected from
the group of benign gastric
ulcer, gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, duodenal
ulcer, duodenal ulcer
associated with Helicobacter pylori, prophylaxis of NSAID-associated gastric
or duodenal ulcer in patients
with an increased risk of gastroduodenal complication who require continued
NSAID treatment and
combination therapy with antibiotics in the eradication of Helicobacter
pylori. In a preferred embodiment
the clinical condition is gastro-oesophageal reflux disease (GERD), in
particular GERD Ito III (according
to Savary/Miller classification, optionally modified according to Siewert).
The dosage forms according to the invention can be combined with other
medicaments, either in various
combinations or in a fixed combination. In connection with the administration
forms according to the
invention, which contain magnesium salt of pantoprazole as active compounds,
combinations with
antimicrobial active compounds and combinations with NSAIDs (nonsteroidal
antiinflammatory drugs) are
particularly worthy of mention. Combination with antimicrobial agents, such as
are employed for the
control of the microorganism Helicobacter pylori (H. pylori), may particularly
be mentioned.
Examples of suitable antimicrobial active compounds (active against
Helicobacter pylori) are described in
EP-A-0 282 131. Examples of antimicrobial agents suitable for the control of
the microorganism
CA 02563162 2006-10-13
WO 2004/098594 PCT/EP2004/050729
-34-
Helicobacter pylori which may be mentioned are, for example, bismuth salts
[e.g. bismuth subcitrate,
bismuth subsalicylate, ammonium bismuth(III) potassium citrate dihydroxide,
bismuth nitrate oxide,
dibismuth tris(tetraoxodialuminate)], but in particular [i-lactam antibiotics,
for example penicillins (such as
benzylpenicillin, phenoxymethylpenicillin, propicillin, azidocillin,
dicloxacillin, flucloxacillin, oxacillin,
amoxicillin, bacampicillin, ampicillin, meziocillin, piperacillin or
azlocillin), cephalosporins (such as cefa-
droxil, celaclor, cefalexin, cefixime, cefuroxime, cefetamet, cefadroxil,
ceftibuten, cefpodoxime, cefotetan,
cefazolin, cefoperazon, ceftizoxime, cefotaxime, ceftazidime, cefamandol,
cefepime, cefoxitin,
cefodizime, cefsulodin, ceftriaxon, cefotiam or cefinenoxime) or other [i-
lactam antibiotics (e.g. aztre-
onam, loracarbef or meropenem); enzyme inhibitors, for example sulbactam;
tetracyclines, for example
tetracycline, oxytetracycline, minocycline or doxycycline; aminoglycosides,
for example tobramycin, gen-
tamicin, neomycin, streptomycin, amikacin, netilmicin, paromomycin or
spectinormycin; amphenicols, for
example chioramphenicol or thiamphenicol; lincomycins and macrolide
antibiotics, for example
clindamycin, lincomycin, erythromycin, clarithromycin, spiramycin,
roxithromycin or azithromycin; poly-
peptide antibiotics, for example colistin, polymixin B, teicoplanin or
vancomycin; gyrase inhibitors, for
example norfioxacin, cinoxacin, ciprofloxacin, pipemidic acid, enoxacin,
nalidixic acid, pefloxacin, flero-
xacin or ofloxacin; nitroimidazoles, for example metronidazole; or other
antibiotics, for example fosfo-
mycin or fusidic acid. Particularly worthy of mention in this connection is
the administration of the mag-
nesium salt of pantoprazole with the combination of a multiplicity of
antimicrobial active compounds, for
example with the combination of a bismuth salt and/or tetracyclines with
metronidazole or the combi-
nation of amoxicillin or clarithromycin with metronidazole and amoxicillin
with clarithromycin.
